AI Article Synopsis
- SARS-CoV-2 mutates over time, leading to new Variants of Concern (VOCs) that can affect how easily the virus spreads, the severity of illness, and how well current antiviral drugs work.
- Recent antiviral drugs like Nirmatrelvir and Ensitrelvir inhibit specific viral proteins (3CLpro), while others like Remdesivir target different proteins (nsp12), but resistance mutations may diminish their effectiveness.
- The review outlines key mutations in these viral proteins and discusses recent advancements in antiviral treatments, highlighting the concern of developing resistance as new variants emerge.
Article Abstract
Purpose Of The Review: SARS-CoV-2 undergoes genetic mutations like many other viruses. Some mutations lead to the emergence of new Variants of Concern (VOCs), affecting transmissibility, illness severity, and the effectiveness of antiviral drugs. Continuous monitoring and research are crucial to comprehend variant behavior and develop effective response strategies, including identifying mutations that may affect current drug therapies.
Recent Findings: Antiviral therapies such as Nirmatrelvir and Ensitrelvir focus on inhibiting 3CLpro, whereas Remdesivir, Favipiravir, and Molnupiravir target nsp12, thereby reducing the viral load. However, the emergence of resistant mutations in 3CLpro and nsp12 could impact the efficiency of these small molecule drug therapeutics.
Summary: This manuscript summarizes mutations in 3CLpro and nsp12, which could potentially reduce the efficacy of drugs. Additionally, it encapsulates recent advancements in small molecule antivirals targeting SARS-CoV-2 viral proteins, including their potential for developing resistance against emerging variants.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11573241 | PMC |
| http://dx.doi.org/10.1007/s40588-024-00229-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!